Patents by Inventor Thomas Ketterer

Thomas Ketterer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11834651
    Abstract: The present invention relates to method for producing and purifying RNA comprising the steps of providing DNA encoding the RNA; transcription of the DNA into RNA; and conditioning and/or purifying of the solution comprising transcribed RNA by one or more steps of tangential flow filtration (TFF).
    Type: Grant
    Filed: May 16, 2023
    Date of Patent: December 5, 2023
    Assignee: CureVac Manufacturing GmbH
    Inventors: Andreas Funkner, Stefanie Dorner, Stefanie Sewing, Johannes Kamm, Norbert Broghammer, Thomas Ketterer, Thorsten Mutzke
  • Patent number: 11760992
    Abstract: The present invention relates to method for producing and purifying RNA comprising the steps of providing DNA encoding the RNA; transcription of the DNA into RNA; and conditioning and/or purifying of the solution comprising transcribed RNA by one or more steps of tangential flow filtration (TFF).
    Type: Grant
    Filed: August 16, 2022
    Date of Patent: September 19, 2023
    Assignee: CureVac Manufacturing GmbH
    Inventors: Andreas Funkner, Stefanie Dorner, Stefanie Sewing, Johannes Kamm, Norbert Broghammer, Thomas Ketterer, Thorsten Mutzke
  • Publication number: 20230287388
    Abstract: The present invention relates to method for producing and purifying RNA comprising the steps of providing DNA encoding the RNA; transcription of the DNA into RNA; and conditioning and/or purifying of the solution comprising transcribed RNA by one or more steps of tangential flow filtration (TFF).
    Type: Application
    Filed: May 16, 2023
    Publication date: September 14, 2023
    Applicant: CureVac Manufacturing GmbH
    Inventors: Andreas FUNKNER, Stefanie DORNER, Stefanie SEWING, Johannes KAMM, Norbert BROGHAMMER, Thomas KETTERER, Thorsten MUTZKE
  • Patent number: 11667910
    Abstract: The present invention relates to method for producing and purifying RNA comprising the steps of providing DNA encoding the RNA; transcription of the DNA into RNA; and conditioning and/or purifying of the solution comprising transcribed RNA by one or more steps of tangential flow filtration (TFF).
    Type: Grant
    Filed: February 3, 2022
    Date of Patent: June 6, 2023
    Assignee: CureVac Manufacturing GmbH
    Inventors: Andreas Funkner, Stefanie Dorner, Stefanie Sewing, Johannes Kamm, Norbert Broghammer, Thomas Ketterer, Thorsten Mutzke
  • Patent number: 11661634
    Abstract: The present invention relates to a method for producing RNA. In particular, the present invention relates to a method for producing RNA, which is scalable and provides RNA at a high purity. The present invention provides a method for producing RNA under GMP and/or cGMP-compliant conditions. The invention further provides specific processes for use as a quality control in the manufacturing of a template DNA and/or in a method for producing RNA, in particular by in vitro transcription.
    Type: Grant
    Filed: July 21, 2022
    Date of Patent: May 30, 2023
    Assignee: CureVac Manufacturing GmbH
    Inventors: Florian Von Der Mülbe, Ladislaus Reidel, Thomas Ketterer, Lilia Gontcharova, Susanne Bauer, Steve Pascolo, Jochen Probst, Andreas Schmid
  • Publication number: 20230157958
    Abstract: The present invention is directed to the field of RNA formulation, in particular to lyophilization of RNA. The invention provides a method for lyophilization of RNA. The present invention further concerns a lyophilized composition obtainable by the inventive method, a pharmaceutical composition, a vaccine and a kit or kit of parts. Moreover, the present invention provides a novel use of a lyoprotectant for lyophilizing RNA, the use of the inventive method in the manufacture of a medicament as well as the first and second medical use of the composition obtainable by the inventive method, the pharmaceutical composition, the vaccine or the kit or kit of parts according to the invention.
    Type: Application
    Filed: August 26, 2022
    Publication date: May 25, 2023
    Applicant: CureVac Manufacturing GmbH
    Inventors: Thomas KETTERER, Thorsten MUTZKE, Michael WIGGENHORN, Frank SCHAUBHUT, Florian VON DER MÜLBE
  • Publication number: 20230151352
    Abstract: The present invention relates to method for producing and purifying RNA comprising the steps of providing DNA encoding the RNA; transcription of the DNA into RNA; and conditioning and/or purifying of the solution comprising transcribed RNA by one or more steps of tangential flow filtration (TFF).
    Type: Application
    Filed: August 16, 2022
    Publication date: May 18, 2023
    Applicant: CureVac Manufacturing GmbH
    Inventors: Andreas FUNKNER, Stefanie DORNER, Stefanie SEWING, Johannes KAMM, Norbert BROGHAMMER, Thomas KETTERER, Thorsten MUTZKE
  • Publication number: 20230053382
    Abstract: The present invention relates to a method for producing RNA. In particular, the present invention relates to a method for producing RNA, which is scalable and provides RNA at a high purity. The present invention provides a method for producing RNA under GMP and/or cGMP-compliant conditions. The invention further provides specific processes for use as a quality control in the manufacturing of a template DNA and/or in a method for producing RNA, in particular by in vitro transcription.
    Type: Application
    Filed: July 21, 2022
    Publication date: February 23, 2023
    Applicant: CureVac Real Estate GmbH
    Inventors: Florian VON DER MÜLBE, Ladislaus REIDEL, Thomas KETTERER, Lilia GONTCHAROVA, Susanne BAUER, Steve PASCOLO, Jochen PROBST, Andreas SCHMID
  • Patent number: 11534405
    Abstract: The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-freeze drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.
    Type: Grant
    Filed: June 18, 2020
    Date of Patent: December 27, 2022
    Assignee: CureVac AG
    Inventors: Fabian Johannes Eber, Benyamin Yazdan Panah, Stefanie Sewing, Thomas Ketterer, Thorsten Mutzke, Tilmann Roos, Michael Sonntag, Michael Wiggenhorn, Katharina Kolland
  • Publication number: 20220387320
    Abstract: The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.
    Type: Application
    Filed: July 11, 2022
    Publication date: December 8, 2022
    Applicant: CureVac AG
    Inventors: Fabian Johannes EBER, Benyamin YAZDAN PANAH, Stefanie SEWING, Thomas KETTERER, Thorsten MUTZKE, Tilmann ROOS, Michael SONNTAG, Michael WIGGENHORN, Katharina KOLLAND
  • Patent number: 11491112
    Abstract: The present invention is directed to the field of RNA formulation, in particular to lyophilization of RNA. The invention provides a method for lyophilization of RNA. The present invention further concerns a lyophilized composition obtainable by the inventive method, a pharmaceutical composition, a vaccine and a kit or kit of parts. Moreover, the present invention provides a novel use of a lyoprotectant for lyophilizing RNA, the use of the inventive method in the manufacture of a medicament as well as the first and second medical use of the composition obtainable by the inventive method, the pharmaceutical composition, the vaccine or the kit or kit of parts according to the invention.
    Type: Grant
    Filed: December 5, 2021
    Date of Patent: November 8, 2022
    Assignee: CureVac Manufacturing GmbH
    Inventors: Thomas Ketterer, Thorsten Mutzke, Michael Wiggenhorn, Frank Schaubhut, Florian Von Der Mülbe
  • Publication number: 20220325273
    Abstract: The present invention relates to method for producing and purifying RNA comprising the steps of providing DNA encoding the RNA; transcription of the DNA into RNA; and conditioning and/or purifying of the solution comprising transcribed RNA by one or more steps of tangential flow filtration (TFF).
    Type: Application
    Filed: February 3, 2022
    Publication date: October 13, 2022
    Applicant: CureVac Real Estate GmbH
    Inventors: Andreas FUNKNER, Stefanie DORNER, Stefanie SEWING, Johannes KAMM, Norbert BROGHAMMER, Thomas KETTERER, Thorsten MUTZKE
  • Patent number: 11458100
    Abstract: The present invention is directed to the field of RNA formulation, in particular to lyophilization of RNA. The invention provides a method for lyophilization of RNA. The present invention further concerns a lyophilized composition obtainable by the inventive method, a pharmaceutical composition, a vaccine and a kit or kit of parts. Moreover, the present invention provides a novel use of a lyoprotectant for lyophilizing RNA, the use of the inventive method in the manufacture of a medicament as well as the first and second medical use of the composition obtainable by the inventive method, the pharmaceutical composition, the vaccine or the kit or kit of parts according to the invention.
    Type: Grant
    Filed: December 5, 2021
    Date of Patent: October 4, 2022
    Assignee: CureVac Manufacturing GmbH
    Inventors: Thomas Ketterer, Thorsten Mutzke, Michael Wiggenhorn, Frank Schaubhut, Florian Von Der Mülbe
  • Patent number: 11446250
    Abstract: The present invention is directed to the field of RNA formulation, in particular to lyophilization of RNA. The invention provides a method for lyophilization of RNA. The present invention further concerns a lyophilized composition obtainable by the inventive method, a pharmaceutical composition, a vaccine and a kit or kit of parts. Moreover, the present invention provides a novel use of a lyoprotectant for lyophilizing RNA, the use of the inventive method in the manufacture of a medicament as well as the first and second medical use of the composition obtainable by the inventive method, the pharmaceutical composition, the vaccine or the kit or kit of parts according to the invention.
    Type: Grant
    Filed: August 17, 2020
    Date of Patent: September 20, 2022
    Assignee: CureVac Real Estate GmbH
    Inventors: Thomas Ketterer, Thorsten Mutzke, Michael Wiggenhorn, Frank Schaubhut, Florian Von Der Mülbe
  • Patent number: 11433027
    Abstract: The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.
    Type: Grant
    Filed: August 20, 2020
    Date of Patent: September 6, 2022
    Assignee: CureVac AG
    Inventors: Fabian Johannes Eber, Benyamin Yazdan Panah, Stefanie Sewing, Thomas Ketterer, Thorsten Mutzke, Tilmann Roos, Michael Sonntag, Michael Wiggenhorn, Katharina Kolland
  • Publication number: 20220168225
    Abstract: The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-freeze drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.
    Type: Application
    Filed: February 21, 2022
    Publication date: June 2, 2022
    Applicant: CureVac AG
    Inventors: Fabian Johannes EBER, Benyamin YAZDAN PANAH, Stefanie SEWING, Thomas KETTERER, Thorsten MUTZKE, Tilmann ROOS, Michael SONNTAG, Michael WIGGENHORN, Katharina KOLLAND
  • Publication number: 20220160638
    Abstract: The present invention is directed to the field of RNA formulation, in particular to lyophilization of RNA. The invention provides a method for lyophilization of RNA. The present invention further concerns a lyophilized composition obtainable by the inventive method, a pharmaceutical composition, a vaccine and a kit or kit of parts. Moreover, the present invention provides a novel use of a lyoprotectant for lyophilizing RNA, the use of the inventive method in the manufacture of a medicament as well as the first and second medical use of the composition obtainable by the inventive method, the pharmaceutical composition, the vaccine or the kit or kit of parts according to the invention.
    Type: Application
    Filed: December 5, 2021
    Publication date: May 26, 2022
    Applicant: CureVac Real Estate GmbH
    Inventors: Thomas KETTERER, Thorsten MUTZKE, Michael WIGGENHORN, Frank SCHAUBHUT, Florian VON DER MÜLBE
  • Publication number: 20220154253
    Abstract: The present invention relates to a method for producing RNA. In particular, the present invention relates to a method for producing RNA, which is scalable and provides RNA at a high purity. The present invention provides a method for producing RNA under GMP and/or cGMP-compliant conditions. The invention further provides specific processes for use as a quality control in the manufacturing of a template DNA and/or in a method for producing RNA, in particular by in vitro transcription.
    Type: Application
    Filed: January 31, 2022
    Publication date: May 19, 2022
    Applicant: CureVac Real Estate GmbH
    Inventors: Florian VON DER MÜLBE, Ladislaus REIDEL, Thomas KETTERER, Lilia GONTCHAROVA, Susanne BAUER, Steve PASCOLO, Jochen PROBST, Andreas SCHMID
  • Patent number: 11274293
    Abstract: The present invention relates to method for producing and purifying RNA comprising the steps of providing DNA encoding the RNA; transcription of the DNA into RNA; and conditioning and/or purifying of the solution comprising transcribed RNA by one or more steps of tangential flow filtration (TFF).
    Type: Grant
    Filed: July 21, 2020
    Date of Patent: March 15, 2022
    Assignee: CureVac Real Estate GmbH
    Inventors: Andreas Funkner, Stefanie Dorner, Stefanie Sewing, Johannes Kamm, Norbert Broghammer, Thomas Ketterer, Thorsten Mutzke
  • Patent number: 11268157
    Abstract: The present invention relates to a method for producing RNA. In particular, the present invention relates to a method for producing RNA, which is scalable and provides RNA at a high purity. The present invention provides a method for producing RNA under GMP and/or cGMP-compliant conditions. The invention further provides specific processes for use as a quality control in the manufacturing of a template DNA and/or in a method for producing RNA, in particular by in vitro transcription.
    Type: Grant
    Filed: June 2, 2020
    Date of Patent: March 8, 2022
    Assignee: CureVac Real Estate GmbH
    Inventors: Florian Von Der Mülbe, Ladislaus Reidel, Thomas Ketterer, Lilia Gontcharova, Susanne Bauer, Steve Pascolo, Jochen Probst, Andreas Schmid